[
  {
    "ts": null,
    "headline": "Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know",
    "summary": "Abbott (ABT) reachead $127.21 at the closing of the latest trading day, reflecting a +0.69% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=479b26a31d6e9d8680b76a80c7d523da762e82573128da5905ceaf633141ac71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742853014,
      "headline": "Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know",
      "id": 133360379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (ABT) reachead $127.21 at the closing of the latest trading day, reflecting a +0.69% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=479b26a31d6e9d8680b76a80c7d523da762e82573128da5905ceaf633141ac71"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (NYSE:ABT) Receives FDA Approval For Coronary IVL System Trial In US",
    "summary": "Abbott Laboratories (NYSE:ABT) has caught investor attention with the FDA’s approval of an Investigational Device Exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System, a significant development within the realm of coronary artery disease treatment. This announcement comes in conjunction with the company's recent robust Q4 2024 earnings results, reporting net income and diluted EPS growth. Additionally, Abbott declared its 405th consecutive quarterly dividend and outlined...",
    "url": "https://finnhub.io/api/news?id=063cdabe65f9efeeb65872d66dd54b08b98efb59167c47113a74d502eee834c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742836821,
      "headline": "Abbott Laboratories (NYSE:ABT) Receives FDA Approval For Coronary IVL System Trial In US",
      "id": 133360381,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) has caught investor attention with the FDA’s approval of an Investigational Device Exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System, a significant development within the realm of coronary artery disease treatment. This announcement comes in conjunction with the company's recent robust Q4 2024 earnings results, reporting net income and diluted EPS growth. Additionally, Abbott declared its 405th consecutive quarterly dividend and outlined...",
      "url": "https://finnhub.io/api/news?id=063cdabe65f9efeeb65872d66dd54b08b98efb59167c47113a74d502eee834c0"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=952faa919d66b544acfe29b4df5cc5dae62eab218e2e5c06100da869277923b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742821209,
      "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 133349488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=952faa919d66b544acfe29b4df5cc5dae62eab218e2e5c06100da869277923b6"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease",
    "summary": "Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to evaluate the treatment of severe calcification in coronary arteries prior to stenting. The TECTONIC Coronary Artery Disease (CAD) Intravascular Lithotripsy (IVL) clinical trial will enroll up to 335 people in 47 sites in the U.S.",
    "url": "https://finnhub.io/api/news?id=abf3a9f43a29facd809bb8fac227dfb2c60e1e252adb4bcda72460643b6419eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742821200,
      "headline": "Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease",
      "id": 133337867,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to evaluate the treatment of severe calcification in coronary arteries prior to stenting. The TECTONIC Coronary Artery Disease (CAD) Intravascular Lithotripsy (IVL) clinical trial will enroll up to 335 people in 47 sites in the U.S.",
      "url": "https://finnhub.io/api/news?id=abf3a9f43a29facd809bb8fac227dfb2c60e1e252adb4bcda72460643b6419eb"
    }
  },
  {
    "ts": null,
    "headline": "Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains",
    "summary": "Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.",
    "url": "https://finnhub.io/api/news?id=9f607916861a251ac2f38010bc94af9ad6339bdd02a60b1848572732d128835f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742820300,
      "headline": "Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains",
      "id": 133337771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.",
      "url": "https://finnhub.io/api/news?id=9f607916861a251ac2f38010bc94af9ad6339bdd02a60b1848572732d128835f"
    }
  },
  {
    "ts": null,
    "headline": "Spinoffs Can Pay Juicy Dividends. 6 Ones to Play.",
    "summary": "Spinoffs Can Pay Juicy Dividends. 6 Ones to Play.",
    "url": "https://finnhub.io/api/news?id=6027893ec93c8538b3cd2acaf99ad07b6cbb94e6776e950cf01aca097c1451d3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1721831400,
      "headline": "Spinoffs Can Pay Juicy Dividends. 6 Ones to Play.",
      "id": 131049981,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Spinoffs Can Pay Juicy Dividends. 6 Ones to Play.",
      "url": "https://finnhub.io/api/news?id=6027893ec93c8538b3cd2acaf99ad07b6cbb94e6776e950cf01aca097c1451d3"
    }
  }
]